Critical care
Does ICU sedative Dex blunt kidney ferroptosis after I/R?
Open access · cc by · source: Europe PMC
In mice and kidney cells, dexmedetomidine lessened ferroptosis-linked renal I/R injury by restraining ACSL4 through α2-AR.
Study at a glance
- Design
- Animal / in-vitro — Mouse bilateral renal I/R (45 min/48 h) plus HEK293T OGD/R with Dex and ACSL4/α2-AR manipulations
- N
- Multiple animal/cell assay groups; no single primary clinical N
- Population
- C57BL/6 mice and HEK293T cells under renal I/R or OGD/R stress
- Outcome
- Ferroptosis, inflammation, and ACSL4 signaling after Dex via α2-AR
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
Dex reduced tissue injury, ferroptosis, and inflammation alongside lower ACSL4; ACSL4 overexpression or α2-AR inhibitor–driven ACSL4 rise reversed Dex protection.
Methodology
Investigators induced bilateral renal hilum ischemia (45 min) and 48 h reperfusion in C57BL/6 mice, ran RNA-seq, and modeled injury with HEK293T OGD/R plus Dex (1 μM), ACSL4 overexpression, and α2-AR inhibition.
Limitations
No human AKI trial; clinical dosing, safety in transplant/shock, and causality beyond these models remain open.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
Dexmedetomidine can protect mouse kidneys after I/R in an ACSL4/ferroptosis-linked framing.
In a renal ischemia/reperfusion mouse model, dexmedetomidine improved Scr/BUN and was tested as acting by inhibiting ACSL4-linked ferroptosis and inflammation via α2-AR signaling.
Evidence for the claim as stated.
Sepsis ALI literature treats ferroptosis as one interconnected injury program among others.
A sepsis-induced ALI review argues lung injury may be attenuated by regulating autophagy, ferroptosis, and pyroptosis across shared nodes (including ACSL4 and GPX4-axis signaling).
Scope note — single-agent mouse I/R study — not a sepsis ALI trial
Limits the claim's scope: a different population, assay, or outcome.
Blocking IRE1/JNK can attenuate ferroptosis-linked renal I/R injury in mice/cells.
Renal ischemia/reperfusion activated IRE1/JNK with ferroptotic tubular injury; inhibiting that axis improved BUN/creatinine and ferroptosis markers, aligning with ferrostatin-1-style protection.
Scope note — another renal I/R ferroptosis-protection model — different drug/node (Dex/ACSL4 vs IRE1/JNK)
Limits the claim's scope: a different population, assay, or outcome.
A mouse renal I/R pharmacologic result and a sepsis ALI pathway review do not establish how much ferroptosis dominates human critical illness versus apoptosis/pyroptosis.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
A mouse renal I/R pharmacologic result and a sepsis ALI pathway review do not establish how much ferroptosis dominates human critical illness versus apoptosis/pyroptosis.
Related papers in this topic
Same topic cluster — not a recommendation engine.